Download MendeleyDiscovery of MK-8189, a Highly Potent and Selective PDE10A Inhibitor for the Treatment of Schizophrenia.
Layton, M.E., Kern, J.C., Hartingh, T.J., Shipe, W.D., Raheem, I., Kandebo, M., Hayes, R.P., Huszar, S., Eddins, D., Ma, B., Fuerst, J., Wollenberg, G.K., Li, J., Fritzen, J., McGaughey, G.B., Uslaner, J.M., Smith, S.M., Coleman, P.J., Cox, C.D.(2023) J Med Chem 66: 1157-1171
- PubMed: 36624931
- DOI: https://doi.org/10.1021/acs.jmedchem.2c01521
- Primary Citation of Related Structures:
8DI4 - PubMed Abstract:
PDE10A is an important regulator of striatal signaling that, when inhibited, can normalize dysfunctional activity. Given the involvement of dysfunctional striatal activity with schizophrenia, PDE10A inhibition represents a potentially novel means for its treatment. With the goal of developing PDE10A inhibitors, early optimization of a fragment hit through rational design led to a series of potent pyrimidine PDE10A inhibitors that required further improvements in physicochemical properties, off-target activities, and pharmacokinetics. Herein we describe the discovery of an isomeric pyrimidine series that addresses the liabilities seen with earlier compounds and resulted in the invention of compound 18 (MK-8189), which is currently in Phase 2b clinical development for the treatment of schizophrenia.
Organizational Affiliation:
Discovery Chemistry, Merck & Co., Inc., West Point, Pennsylvania 19486, United States.
